Lava Therapeutics Company

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.
Industry: Atrificial Vectors and Immune Cells
Headquarters: Utrecht, Utrecht, The Netherlands
Founded Date: 2016-01-01
Employees Number: 51-100
Funding Status: IPO
Investors Number: 9
Total Funding: 102854807
Estimated Revenue: $1M to $10M
Last Funding Date: 2020-09-17
Last Funding Type: Series C

Visit Website
info@lavatherapeutics.com
Register and Claim Ownership